TrialScientific reports2017

A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients.

Hui-Jen Tsai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.